Skip to main content
Equibles
SIGY logo

SIGY · Sigyn Therapeutics, Inc. · Metrics

Track SIGY — free

Use SIGY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SIGY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.03 At close · Nov 6
Rebalance outlook locked
Going-concern doubt — flagged Nov 14, 2025

Substantial doubt about the company's ability to continue as a going concern.

“The Company had an accumulated deficit of $17,379,978 at September 30, 2025, had a working capital deficit of $3,903,920 at September 30, 2025, had net losses of $578,503 and $2,698,254, and $1,196,923 and $2,817,394 for the three and nine months ended September 30, 2025 and 2024, respectively, and net cash used in operating activities of $646,208 and $582,218 for the nine months ended September 30, 2025 and 2024, respectively, with no revenue earned since inception, and a lack of operational history. These matters raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Nov 14, 2025
Market Cap
$44,951
Shares
1.61M
Volume · Nov 6 2000 Avg daily vol (3M) 22.72K

SIGY metrics

51 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.03
Market cap
$44,951

Price action

23 metrics
Price change (1W)
+0.0%
Price change (30D)
-22.2%
Price change (3M)
-28.2%
Price change (6M)
-30.0%
Price change (YTD)
—
Price change (1Y)
-98.6%
Trailing year
Price change (5Y)
—
52-week high
$2.00
52-week low
$0.02
Change from 52-week high
-98.6%
Change from 52-week low
+33.3%
Annualized volatility
435.0%
Annualized volatility (3M)
—
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
3.2
RSI (14D)
46.5
Price vs SMA 50
-12.0%
Price vs SMA 200
-97.9%
Avg volume (3M)
22,722
Relative volume
0.1
Average dollar volume
$761

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
1.61M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
4.5×
reciprocal yield 22.1%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-7,165.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
63.4%
Operating margin
-361.4%
Trailing 12 months
Net margin
-2,145.3%
Gross profit (TTM)
$6,292
Operating profit (TTM)
−$1.88M
Net income (TTM)
−$3.22M
Trailing 12 months
Diluted EPS (TTM)
$-1.93
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-3.39

Growth

11 metrics
Revenue growth YoY
-88.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$9,929
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+26.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
+27.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-2,375.9%
Debt / equity
—
Current ratio
0.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$3.77M
Latest balance sheet
Cash & equivalents
$85,571
Total assets
$135,571
Total debt
$3.85M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$936,426
Capital expenditures (TTM)
—
R&D (TTM)
$140,101
SG&A (TTM)
—
Stock compensation (TTM)
$187,500
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
1
13F filer change QoQ
+1
Institutional ownership
3.3%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
1.0
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1642159 CUSIP 82674U205 13F (30d) 1 filings 1 filers Visit website Investor relations